NDAINTRAVENOUSPOWDER
Approved
Sep 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
LEVOLEUCOVORIN CALCIUM (levoleucovorin calcium) by Teva is high-dose methotrexate therapy levoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Approved for autism spectrum disorder, language disorders. First approved in 2016.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Levoleucovorin calcium is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid used as a rescue agent after high-dose methotrexate therapy and as an adjunct to fluorouracil in colorectal cancer treatment. It counteracts the toxic effects of folic acid antagonists by providing reduced folate cofactors without requiring the dihydrofolate reductase enzyme. The drug is administered intravenously as a powder formulation.
$0.013BPart D
PeakProduct is in peak commercial stage with modest Medicare spending; team size likely stable with limited growth opportunity.
Mechanism of Action
High-Dose Methotrexate Therapy Levoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Levoleucovorin does not require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of “one-carbon” moieties.…
Worked on LEVOLEUCOVORIN CALCIUM at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.